Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system

American Journal of Obstetrics and Gynecology

Volumn 191, Issue 4, 2004, Pages 1164-1172

  Günthert, Andreas R ^a   Gründker, Carsten ^a   Bongertz, Till ^a   Schlott, Thilo ^a   Nagy, Attila ^b   Schally, Andrew V ^b   Emons, Günter ^a,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c D 37075 Göttingen Germany ^*  (Germany)

Author keywords

AN 152; Apoptosis; Endometrial cancer; Multidrug resistance 1; Ovarian cancer

Indexed keywords

CHLOROQUINE; CYTOTOXIC AGENT; DOXORUBICIN; DYFLOS; GENE PRODUCT; GLYCOPROTEIN P; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SECRETION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG MONITORING; ENDOMETRIUM CANCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PHOSPHORIC TRIESTER HYDROLASES; RECEPTORS, LH; TUMOR CELLS, CULTURED;

EID: 7044234874     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.04.020     Document Type: Article

References (31)

1. Emons G., Ortmann O., Schulz K.D., Schally A.V. Growth-inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab. 8:1997;355-362
2. Schally A.V. Luteinizing hormone-releasing hormone analogs; their impact on the control of tumorigenesis. Peptides. 20:1999;1247-1262
3. Miyazaki M., Nagy A., Schally A.V., Lamharzi N., Halmos G., Szepeshazi K., et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst. 89:1997;1803-1809
4. Westphalen S., Kotulla G., Kaiser F., Krauß W., Werning G., Elsässer H.P., et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 17:2000;1063-1069
5. Nagy A., Plonowski A., Schally A.V. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci U S A. 97:2000;829-834
6. Szepeshazi K., Schally A.V., Nagy A., Halmos G., Groot K. Targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anticancer Drugs. 8:1997;974-987
7. Gründker C., Völker P., Griesinger F., Ramaswamy A., Nagy A., Schally A.V., et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol. 187:2002;528-537
8. Ozalp S.S., Yalcin O.T., Tanir M., Kabukcuoglu S., Etiz E. Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur J Gynaecol Oncol. 23:2002;337-340
9. Yokoyama Y., Sato S., Fukushi Y., Sakamoto T., Futagami M., Saito Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 25:1999;387-394
10. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs. 47:1994;223-258
11. Zhang W., Ling V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol. 184:2000;17-26
12. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., et al. Characterization of human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:1983;5379-5389
13. Fogh J., Wright W.C., Loveless J.D. Absence of HeLA cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 58:1977;209-214
14. Simon W.E., Albrecht M., Hänsel M., Dietel M., Hölzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst. 70:1983;839-845
15. Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi H. Establishment of a new endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynaecol Jpn. 37:1985;1103-1111
16. Kuramoto H., Tamura S., Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 114:1972;1012-1019
17. Emons G., Ortmann O., Becker M., Irmer G., Springer B., Laun R., et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. 53:1993;5439-5446
18. Emons G., Schröder B., Ortmann O., Westphalen S., Schulz K.-D., Schally A.V. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 77:1993;1458-1464
19. Nicoletti I., Migloriati G., Pagliacci M.C., Grignani F., Ricardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:1991;271-279
20. Wang X., Krebs L.J., Al-Nuri M., Pudvar H.E., Ghosal S., Liebow C., et al. A chemically labelled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci U S A. 96:1999;11081-11084
21. Fojo A., Hamilton T.C., Young R., Ozols R. Multidrug resistance in ovarian cancer. Cancer. 60:1987;2075-2080
22. Bourhis J., Goldstein L.J., Riou G., Pastan I., Gottesmann M.M., Bénard J. Expression of a multidrug resistance gene in ovarian carcinomas. Cancer Res. 49:1989;5062-5065
23. Schneider J., Rubio M.P., Barbazan M.J., Rodriguez-Escudero F.J., Seizinger B.R., Castresana J.S. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynaecologic tumors. J Natl Cancer Inst. 86:1994;850-855
24. Schneider J., Effert T., Centeno M.M., Rodriguez-Escudero F.J., Volm M. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer. 29:1993;554-558
25. Randall M.E., Spirtos N.M., Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr. 19:1995;13-15
26. Schneider Y.J., Trouet A. Effect of chloroquine and methylamine on endocytosis of fluorescein-labelled controlled IgG and of anti-(plasma membrane) IgG by cultured fibroblasts. Eur J Biochem. 118:1981;33-38
27. Rooseboom M., Commandeur J.N., Vermeulen N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 56:2004;53-102
28. St'astny M., Strohalm J., Plocova D., Ulbrich K., Rihova B. A possibility to overcome P-glycoprotein (Pgp)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur J Cancer. 35:1999;459-466
29. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release. 54:1998;223-233
30. Arencibia J.M., Schally A.V., Krupa M., Bajo A.M., Nagy A., Szepeshazi K., et al. Targeting of doxorubicin bES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol. 19:2001;571-577
31. Gründker C., Schulz K., Günthert A.R., Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κ B-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab. 85:2000;3815-3820